Póti Zsuzsa, Mayer Arpád
Uzsoki Utcai Kórház Fővárosi Onkoradiológiai Központ Budapest.
Orv Hetil. 2013 May 26;154(21):803-9. doi: 10.1556/OH.2013.29618.
The advantages of cisplatin based radiochemotherapy have been proven for over one and a half decades, particularly in the treatment of advanced solid tumours. In head and neck, and cervical tumours results of prospective studies are available. Those showed that both in the early and advanced stages, local control and overall survival rates are better than radiotherapy alone. The effect of cisplatin can be probably intensified with novel, more effective molecules, such as m-TOR inhibitors and tirapazamine. The authors review cisplatin and non-cisplatin based radiochemotherapy protocols, which improve previous treatment results. It should be considered, however, radiotherapy for cervical cancer can cause hematological, urogenital and intestinal toxicity, similarly to other combined treatments. The authors briefly outline international recommendations and their own experience for the prevention of these side-effects.
基于顺铂的放化疗的优势已得到超过十五年的证实，尤其是在晚期实体瘤的治疗中。在头颈部和宫颈癌方面，有前瞻性研究的结果。这些结果表明，无论是早期还是晚期，局部控制率和总生存率都优于单纯放疗。顺铂的疗效可能会通过新型、更有效的分子如m-TOR抑制剂和替拉扎明得到增强。作者回顾了基于顺铂和非顺铂的放化疗方案，这些方案改善了以往的治疗效果。然而，应该考虑到，与其他联合治疗一样，宫颈癌放疗会导致血液学、泌尿生殖系统和肠道毒性。作者简要概述了预防这些副作用的国际建议和他们自己的经验。
